✓ Graphs ✓ Tables ✓ Reports
 
Format: www.xyz.com or *.gov
Where ▼
Where ▲
Date:
Note: Results will be PDF and Excel – which we can date reliably. For PDFs, it will either be the date the PDF was creater, or the date visible in the graph or chart.
When ▼
When ▲
What ▼
What ▲

Data & statistics on Breast Cancer Therapy – 140963 results
Hover over me
Breast cancer therapy planning - a sequential decision making problem

Breast cancer therapy planning - a sequential decision making problem

www.itwm.fraunhofer.de/fileadmin/ITWM-Media/Zentral/Pdf/Berichte_ITWM/2013/bericht_237.pdf

Breast cancer therapy planning - a sequential decision making problem Matching ...
adjuvant case history(X, X′ )  fulfilled : ∃a, a′ ∈ {Breast conserving therapy ...
7 Sequential decision making In the terminology of multi-criteria decision making, [Ehrgott(2005)], (6) and (1) form the decision spaces, where (10) serves as a feasible set in (1), and (2) is the criterion space of the therapy planning problem

Nov 2013 | Fraunhofer-ITWM: Willkommen am Fraunhofer ITWM!
Original Url: http://www.itwm.fraunhofer.de/fileadmin/ITWM-Media/Zentral/Pdf/Berichte_ITWM/2013/bericht_237.pdf
Figure 6. Dose-response ranges for tamoxifen in breast cancer therapy. This figure demonstrates the NMDRC, also called flare, in tamoxifen treatments. As the circulating dose of tamoxifen increases when treatment starts, patients initially experience flare, i.e. growth of the tumor (546), followed by a decrease in tumor size as the circulating levels of tamoxifen rise into the therapeutic range (676, ...

Figure 6. Dose-response ranges for tamoxifen in breast cancer therapy. This figure demonstrates the NMDRC, also called flare, in tamoxifen treatments. As the circulating dose of tamoxifen increases ...

edrv.endojournals.org/content/early/2012/03/14/er.2011-1050.full.pdf

use. The lowest dose-response range, the range of flare, stimulated breast cancer growth and symptoms in some patients with hormone-dependent cancer. The next higher ...
was not detected in the phase I trials and was determined only for tamoxifen in breast cancer

Mar 2012 | Endocrine Reviews
Original Url: http://edrv.endojournals.org/content/early/2012/03/14/er.2011-1050.full.pdf
Advances in Breast Cancer Therapy: A Focus on Patient Populations and Therapeutic Settings Presentation 3

Advances in Breast Cancer Therapy: A Focus on Patient Populations and Therapeutic Settings Presentation 3

www.peerviewpress.com/files/presentations/14877/printtranscript/14877.pdf

Advances in Breast Cancer Therapy: A Focus on Patient Populations and Therapeutic Settings Presentation 2 Please click the Evaluation tab to share your thoughts on this activity. Go online to participate in this activity: www.peervoice.com/d/pvs18 Slide

Jun 2012 | Continuing Medical Education (CME) Resource - PeerView Press
Original Url: http://www.peerviewpress.com/files/presentations/14877/printtranscript/14877.pdf
Game Changers in Breast Cancer Therapies

Game Changers in Breast Cancer Therapies

www.trimarkpublications.com/product_images/samples/gamechangerssample.pdf

May 2012 Game Changers in Breast Cancer Therapies May 2012 INDEX OF FIGURES ...
Breast Cancer Standard of Care for the Treatment of ER+ Breast Cancer Adjuvant Chemotherapy in ER+ Breast Cancer Adjuvant Hormone Therapy in ER+ Breast Cancer Afinitor Expected to be a Game Changer in ER+ Breast Cancer mTOR/pI3k Resistance Novartis

May 2012 | TriMark Publications is a Global Leader in Biotechnology, Healthcare and Life Sciences Publishing
Original Url: http://www.trimarkpublications.com/product_images/samples/gamechangerssample.pdf
Prior Breast Cancer Therapy of Patients in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)

Prior Breast Cancer Therapy of Patients in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)

media.pfizer.com/files/products/uspi_aromasin.pdf

Table 2. Prior Breast Cancer Therapy of Patients in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population) Exemestane (N = 2352) Tamoxifen (N = 2372) Parameter Type of surgery, n (%): Mastectomy Breast-conserving ...
PgR status. After a median duration of therapy of 27 months and with a median

Dec 2008 | Pfizer Pfizer: the world's largest research-based pharmaceutical company
Original Url: http://media.pfizer.com/files/products/uspi_aromasin.pdf
Prior Breast Cancer Therapy of Patients in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)
357 more results from this site ▶

Prior Breast Cancer Therapy of Patients in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)

www.accessdata.fda.gov/drugsatfda_docs/label/2005/020753s006lbl.pdf

AROMASIN® (exemestane tablets) NDA 20-753/S-006 October 4, 2005 baseline tumor characteristics are presented in Table 1. Prior breast cancer therapy is summarized in Table 2. ...
Table 2. Prior Breast Cancer Therapy of Patients in the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population) Exemestane (N = 2352) Tamoxifen (N = 2372) Parameter Type of surgery, n (%): Mastectomy Breast-conserving

Oct 2005 | default.htm - redirect page – 357 more results from this site
Original Url: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020753s006lbl.pdf
Respectful Insolence: Does genistein interfere with breast cancer therapy?

Respectful Insolence: Does genistein interfere with breast cancer therapy?

scienceblogs.com/insolence/2008/09/does_genistein_interfere_with_breast_can.php

Respectful Insolence: Does genistein interfere with breast cancer therapy? ...
post-menopausal breast cancer. First, they gave the mice AD, which was converted ...
the maximum growth rate of the breast cancer tumors. Next, they added Letrozole

Sep 2008 | ScienceBlogs
2010 7760557 Primary Breast Cancer Therapy Group

2010 7760557 Primary Breast Cancer Therapy Group

officeofbudget.od.nih.gov/pdfs/FY12/NEWConsolidate_summary_final_5-15-2012.pdf

5 U10CA021661-34 5 U10CA025224-31 5 U10CA029511-31 2010 7781358 Radiation Therapy Oncology Group 2010 7772350 North Central Cancer Treatment Group 2010 7759154 Quality Assurance Review Center NCI NCI NCI ...
2010 7943983 RADIATION-ENHANCED NANOBIOPOLYMER THERAPEUTICS THROUGH THE BLOOD ...
of localized prostate cancer following initial radia NCI 5 RC1CA146337-02 2010 7936202 Targeted Photoactivatable Nanocells to Image and Treat Metastic Ovarian Cancer NCI

Jan 2010 | Welcome to the Office of Budget
Original Url: http://officeofbudget.od.nih.gov/pdfs/FY12/NEWConsolidate_summary_final_5-15-2012.pdf
Breast cancer therapeutic benefits assessment.

Breast cancer therapeutic benefits assessment.

www.hsc.wvu.edu/mbrcc/fs/GuoLab/pdfs/supplementary-Guo-CCR-V2.pdf

Table 9. Breast cancer therapeutic benefits assessment. Average RFS (days) Hormonal Alone 1005 (21 patients) 2496 (15 patients) 2734 (20 patients) Chemo Alone 613 (5 patients) 1478 (1 patient) 3632 (4 patients) Chemo + Hormonal 1048 (10 patients) 2262 ...
To assess the therapeutic benefits for each risk group, average relapse-free survival days were compared for patients receiving adjuvant therapy in each group using the data from Sotiriou et al. (1). Specifically, therapeutic effects for patients

Jan 2007 | WVU Health Sciences Center
Original Url: http://www.hsc.wvu.edu/mbrcc/fs/GuoLab/pdfs/supplementary-Guo-CCR-V2.pdf
IMPROVEMENT OF BREAST CANCER THERAPY BY USING NANOVECTOR DELIVERY SYSTEMS

IMPROVEMENT OF BREAST CANCER THERAPY BY USING NANOVECTOR DELIVERY SYSTEMS

www.salute.gov.it/imgs/C_17_pagineAree_3023_listaFile_itemName_4_file.pdf

Optimizing and integrating the delivery of primary care services for risky drinkers in Region Friuli‐Venezia Giulia RF‐2010‐ The early identification of the free radical disease of the newborn. New therapeutic strategies. RF‐2010‐ Proposal

Jan 2010 | Ministero della Salu
Original Url: http://www.salute.gov.it/imgs/C_17_pagineAree_3023_listaFile_itemName_4_file.pdf
Related searches: bone metastases therapy, colorectal cancer drug, conjunctivitis therapy, relative risk ratio of recurrence, darbepoetin alfa

Hints & help

Language. English only please... for now.
Phrase search. You can use double quotes to make phrases (e.g. "mobile phones").
Booleans. You can use a plus ‘+’ to make a word mandatory, or a minus ‘–‘ to exclude it (e.g. +gas –oil production)
Vocabulary. We have only limited synonyms - please try different words in your query.
Questions? Please email us: helpdesk [at] zanran [dot] com